About GlycoMar
GlycoMar is a company based in Oban (United Kingdom) founded in 2005. GlycoMar has raised $1.35 million across 5 funding rounds from investors including European Union, EIC Fund and Epiphany Capital. GlycoMar operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Oban, United Kingdom
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website glycomar.com
- Social LinkedIn X Facebook
- Total Equity Funding$1.35M (USD)
in 5 rounds
- Latest Funding Round$53.68K (USD), Grant
Mar 2017
- InvestorsEuropean Union
& 3 more
Funding Insights of GlycoMar
GlycoMar has successfully raised a total of $1.35M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $53.68 thousand completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.35M
- Total Rounds 5
- Last Round Grant — $53,678
- First Round $317,255
(Dec 2007)
- Investors Count 4
All 5 funding rounds of GlycoMar with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2017 | $53,678 | Grant | – | – | |
| Dec 2016 | $53,305 | Grant | – | – | |
| Dec 2013 | $1.04M | Series A | – | – | |
| Mar 2008 | $85,414 | Grant | – | – | – |
| Dec 2007 | $317,255 | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in GlycoMar
GlycoMar has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, EIC Fund and Epiphany Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
- | – | epiphanycapital.co.uk | - | |
An investment group focused on life sciences and clinical development. | 1987 | technomarkls.com | - | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for GlycoMar
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of GlycoMar
3 dated milestones of GlycoMar across 12 years, from founding to its latest funding, stage changes and deals.
- Founded GlycoMar is founded.
- Funding First funding round of $317K.
- Funding Latest funding round, Grant, of $54K.
Competitors of GlycoMar
GlycoMar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of GlycoMar
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GlycoMar
Websites that share an audience with GlycoMar (glycomar.com).
Websites whose visitors overlap most with GlycoMar. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| syntechresearch.com | 100% | 3.8K | #4,799,367 | View details | |
| geomarinebiotech.com | 99% | – | – | View details |
Similar companies to GlycoMar
10 companies that operate in the same segment as GlycoMar (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GlycoMar
GlycoMar was founded in 2005 and raised its 1st funding round 2 years after it was founded.
GlycoMar is headquartered in Oban, United Kingdom. It is registered at Oban, Scotland, United Kingdom.
GlycoMar is a funded company, having raised a total of $1.35M across 5 funding rounds to date. The company's 1st funding round was a Seed of $317.26K, raised on Dec 2007.
GlycoMar Limited was founded in 2005 in Oban, Scotland, where research and development activities center on marine organisms for identifying drug candidates. A glycobiology platform is applied to target microalgae-derived saccharide products for pharmaceutical, healthcare, cosmetic, and nutraceutical sectors. Preclinical pipelines have been advanced, including collaborations with Verona Pharma. Glycobiology services are provided to support external projects.
GlycoMar's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
GlycoMar has 4 investors. Key investors include European Union, EIC Fund, Epiphany Capital, and Technomark LS.